DICLOFENAC SODIUM Drug Interactions

Clinical Management

The primary clinical effect is a significantly increased risk of bleeding, particularly gastrointestinal bleeding (e.g., ulcers, hemorrhage) and other serious bleeding events. The risk of major gastrointestinal bleeding can be 3-15 times higher when NSAIDs are combined with antiplatelets compared to either drug alone, with a reported incidence of 2-4% per year for serious GI events. This combination should be avoided if possible. If concomitant therapy is unavoidable and the cardiovascular benefit outweighs the bleeding risk, consider prescribing a proton pump inhibitor (PPI) for gastroprotection. Closely monitor for signs of bleeding (e.g., black/tarry stools, unusual bruising, fatigue) and anemia. Alternative pain management strategies or NSAIDs with lower GI risk (e.g., celecoxib with PPI) may be considered, but still require caution.

Clinical Management

This combination significantly elevates the risk of major bleeding events, including gastrointestinal hemorrhage, intracranial hemorrhage, and other serious bleeding. Studies show a 2-4 fold increased risk of major bleeding compared to apixaban alone, with GI bleeding being the most common. Symptoms may include black, tarry stools, vomiting blood, or unusual bruising. This combination should generally be avoided due to the high risk of severe bleeding. If an NSAID is absolutely necessary, consider alternatives like acetaminophen for pain relief. If NSAID use is unavoidable, use the lowest effective dose for the shortest duration, and monitor closely for signs of bleeding. Proton pump inhibitors (PPIs) may be considered to reduce GI bleeding risk, but do not eliminate it.

Clinical Management

The primary clinical effect is a substantially increased risk of bleeding, which can manifest as gastrointestinal bleeding (e.g., melena, hematemesis), epistaxis, hematuria, bruising, or more severe internal hemorrhages. Studies suggest that the risk of major bleeding can be several-fold higher when NSAIDs are combined with DOACs compared to DOACs alone. This combination should be avoided if possible. If concomitant use is unavoidable, the patient must be closely monitored for signs and symptoms of bleeding, and the lowest effective dose of diclofenac for the shortest duration should be used. Consider alternative pain management strategies that do not increase bleeding risk, such as acetaminophen. Proton pump inhibitor prophylaxis may be considered if NSAID use is essential, but it does not eliminate the systemic bleeding risk.

Clinical Management

Patients are at a significantly increased risk for serious bleeding events, including gastrointestinal hemorrhage, intracranial hemorrhage, and other major bleeding. The risk of GI bleeding can be 3-15 times higher when NSAIDs are co-administered with anticoagulants compared to anticoagulants alone. This combination should generally be avoided due to the high risk of serious bleeding. If co-administration is absolutely necessary, patients must be closely monitored for signs of bleeding, and a proton pump inhibitor (PPI) should be considered for GI protection. Alternative pain management strategies that do not involve NSAIDs should be explored.

Clinical Management

The primary clinical effect is a substantially increased risk of bleeding, including gastrointestinal bleeding (e.g., ulcers, hemorrhage), intracranial hemorrhage, and other systemic bleeding events. This combination can increase the risk of serious bleeding events by 3 to 15 times compared to anticoagulant monotherapy, depending on the specific NSAID and patient risk factors. This combination should generally be avoided. If an NSAID is absolutely necessary, consider alternative pain management strategies or a short course of a COX-2 selective inhibitor with proton pump inhibitor co-therapy, under strict monitoring. Closely monitor for any signs of bleeding (e.g., black stools, unusual bruising, prolonged bleeding from minor cuts) and hemoglobin levels. Reassess the need for both medications frequently.

Clinical Management

Avoid concomitant use if possible. If co-administration is unavoidable, closely monitor the patient for signs of bleeding and frequently check INR levels, adjusting warfarin dose as needed. Consider gastroprotective agents and alternative pain management strategies.

Clinical Management

This combination significantly increases the risk of major bleeding, especially gastrointestinal bleeding, which can be life-threatening. The risk of GI bleeding is estimated to be 3 to 15 times higher when NSAIDs are co-administered with warfarin. Other potential effects include increased bruising, nosebleeds, and hematuria. This combination should generally be avoided. If an NSAID is absolutely necessary, a proton pump inhibitor (PPI) should be co-prescribed to reduce GI bleeding risk, and the patient's INR should be monitored very closely and frequently. Alternatives to NSAIDs for pain, such as acetaminophen or opioids, should be considered. If unavoidable, use the lowest effective dose for the shortest duration possible.

Clinical Management

The primary clinical effect is a substantially increased risk of bleeding, particularly gastrointestinal bleeding, which can manifest as melena, hematemesis, or severe anemia. Other bleeding events like intracranial hemorrhage or hematuria are also elevated. The risk of serious GI bleeding with NSAIDs and anticoagulants can be 3-15 times higher than with anticoagulants alone. This combination should generally be avoided due to the high risk of serious bleeding. If an NSAID is absolutely necessary, consider alternatives with lower GI risk (e.g., acetaminophen) or a COX-2 selective NSAID with concomitant proton pump inhibitor therapy, under close medical supervision. Monitor for signs and symptoms of bleeding.

Clinical Management

Patients are at a substantially increased risk of bleeding, including gastrointestinal bleeding (e.g., stomach ulcers, melena, hematemesis), intracranial hemorrhage, and other serious bleeding events. The risk of major bleeding can be several-fold higher compared to anticoagulant monotherapy, with gastrointestinal bleeding being the most common serious adverse event. Concomitant use of diclofenac and edoxaban should generally be avoided due to the high risk of serious bleeding. If pain management is necessary, consider alternative analgesics such as acetaminophen. If an NSAID is absolutely essential and no other options exist, use the lowest effective dose for the shortest possible duration, and monitor closely for signs of bleeding. Consider gastroprotective agents (e.g., proton pump inhibitors) if NSAID use is unavoidable.

Clinical Management

The primary clinical effect is a substantially increased risk of serious bleeding, including gastrointestinal hemorrhage, intracranial hemorrhage, and other major bleeding events. Patients may experience symptoms like black tarry stools, blood in vomit, easy bruising, or prolonged bleeding from minor cuts. The risk of major gastrointestinal bleeding can be several-fold higher compared to either drug alone. This combination should generally be avoided. If both agents are absolutely necessary, use the lowest effective dose of diclofenac for the shortest possible duration, and consider a gastroprotective agent (e.g., proton pump inhibitor). Closely monitor for signs of bleeding, and regularly assess coagulation parameters (e.g., aPTT for unfractionated heparin). Explore alternative pain management strategies that do not increase bleeding risk.

Clinical Management

The primary risk is a significantly increased chance of major bleeding, including gastrointestinal hemorrhage, intracranial hemorrhage, and other site-specific bleeding. The risk of GI bleeding with NSAID plus anticoagulant is estimated to be 3 to 15 times higher than with anticoagulant alone. Symptoms may include black, tarry stools, blood in vomit, severe abdominal pain, or unusual bruising. This combination should generally be avoided. If concurrent use is absolutely necessary, it should be done with extreme caution, close monitoring for signs of bleeding, and only under strict medical supervision. Consider alternative pain management strategies that do not increase bleeding risk, such as acetaminophen or opioids. If an NSAID is unavoidable, a COX-2 selective agent might offer a slightly lower GI bleeding risk, but the overall bleeding risk with enoxaparin remains high.

Clinical Management

The primary clinical effect is a substantially increased risk of bleeding, particularly gastrointestinal bleeding, but also bleeding from other sites. This can manifest as melena, hematemesis, hematuria, or excessive bruising. The risk of major gastrointestinal bleeding with NSAID plus anticoagulant therapy can be 3 to 15 times higher than with anticoagulant monotherapy. This combination should generally be avoided due to the high risk of bleeding. If an NSAID is absolutely necessary, consider alternative pain management strategies or a short course of a COX-2 selective NSAID, though the bleeding risk remains significant. Close monitoring for signs and symptoms of bleeding is essential, and patients should be educated on what to watch for. Gastric protection with a proton pump inhibitor should be considered if the combination is unavoidable.

Clinical Management

The primary clinical effect is a significantly increased risk of bleeding, including gastrointestinal bleeding (e.g., ulcers, hemorrhage), bruising, nosebleeds, and prolonged bleeding from cuts. The risk of serious GI bleeding can be several-fold higher compared to either drug alone, potentially leading to anemia or requiring hospitalization. This combination should generally be avoided due to the high bleeding risk. If concurrent use is unavoidable, patients must be closely monitored for signs of bleeding (e.g., black/tarry stools, unusual bruising, weakness). Consider alternative pain relief not affecting platelets or gastric mucosa, such as acetaminophen. If an NSAID is absolutely necessary, use the lowest effective dose for the shortest duration, and consider a proton pump inhibitor for gastroprotection.

Clinical Management

The primary clinical effect is a significantly increased risk of bleeding, particularly gastrointestinal bleeding (e.g., ulcers, hemorrhage), but also other forms of bleeding such as epistaxis, hematuria, and bruising. The risk of major bleeding can be several-fold higher compared to ticagrelor alone, potentially leading to hospitalization, transfusions, or even fatal outcomes. This combination should be avoided if possible. If an NSAID is absolutely necessary, consider alternative pain management strategies or a short course of a COX-2 selective NSAID with careful monitoring and gastric protection (e.g., proton pump inhibitor). Closely monitor for any signs of bleeding (e.g., black/tarry stools, coffee-ground vomit, unusual bruising).

Clinical Management

The primary clinical effect is a substantially increased risk of serious bleeding, including gastrointestinal bleeding (e.g., ulcers, hemorrhage), intracranial hemorrhage, and other systemic bleeding events. Studies indicate that the combination of NSAIDs and antiplatelets can increase the risk of upper gastrointestinal bleeding by several-fold compared to either drug alone. This combination should generally be avoided due to the high bleeding risk. If concurrent use is unavoidable, patients must be closely monitored for signs of bleeding (e.g., black/tarry stools, unusual bruising, blood in urine/stools). Consider alternative pain management strategies that do not involve NSAIDs, or use the lowest effective dose of diclofenac for the shortest duration possible, along with gastroprotective agents like proton pump inhibitors.

Clinical Management

Patients taking diclofenac and prasugrel concurrently face a significantly elevated risk of major bleeding events, including gastrointestinal hemorrhage, intracranial hemorrhage, and other site-specific bleeding. The risk of GI bleeding can be several times higher compared to taking either drug alone, potentially leading to anemia, hospitalization, or life-threatening complications. This combination should generally be avoided due to the high risk of major bleeding. If an NSAID is absolutely necessary, consider alternative pain management strategies or a COX-2 selective NSAID for the shortest duration possible, along with a proton pump inhibitor (PPI) for gastroprotection. Closely monitor for any signs of bleeding (e.g., black stools, easy bruising, nosebleeds) and hemoglobin levels. Discuss with the prescribing physician to assess the risk-benefit and explore safer alternatives.

Clinical Management

This combination substantially increases the risk of serious bleeding, including gastrointestinal bleeding (e.g., ulcers, hemorrhage), intracranial hemorrhage, and other systemic bleeding. Symptoms may include black, tarry stools, vomiting blood, unusual bruising, or prolonged bleeding from cuts. The risk of GI bleeding with NSAIDs alone is increased 2-4 fold, and this risk is further amplified when combined with antiplatelets. This combination should generally be avoided due to the high risk of bleeding. If concurrent use is absolutely necessary, patients must be closely monitored for signs of bleeding, and the lowest effective doses for the shortest duration should be used. Consider alternative pain management strategies or antiplatelet agents with lower interaction potential if possible, or a proton pump inhibitor for GI protection.